• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Bio-Matrix Scientific Group, Inc. Receives and Processes First Cord Blood Specimens As Part of the Company's Quality Assurance Program

Posted on: Wednesday, 1 October 2008, 09:00 CDT

Bio-Matrix Scientific Group Inc. (OTCBB:BMSN), a biotechnology company focused on adult stem cell processing and cryogenic storage, announced today that they have received and processed human umbilical cord blood units as part of their long-term liquid nitrogen storage quality assurance and testing program.

The processing and storage of these cord blood stem cells is solely for the purpose of validating the handling, processing and cryopreservation of cord blood specimens. The cord blood stem cells were obtained from donor cord blood units and processed in the Company's cord blood division laboratory using well established separation techniques aimed at enriching the stem cell content. The Company will utilize these cord blood stem cells to enhance its ongoing quality assurance program for its cellular storage division by allowing periodic monitoring of the cellular viability of these specimens over their storage life, assuring our clients of optimal cryostorage conditions.

In addition, these cryopreserved stem cells have been used to validate Bio-Matrix's procedure for the eventual shipping of stored cord blood stem cells for transplantation purposes, often for life-threatening diseases. Viability of each specimen was assessed prior to shipment and upon receipt at the receiving institution. Maintenance of the viability of these specimens during shipment combined with extensive temperature data logging assures the receiving patient of optimal condition of stem cells to be transplanted.

Stem cell cryopreservation and storage involves the collection and processing of stem cells from tissue, such as cord blood and the storage in liquid nitrogen. These banked stem cells can be preserved in this way for many years and may be used in future medical procedures program.

The Company is currently finalizing several previously announced potential contracts and is in discussions with several other companies regarding the processing and storage of stem cells derived from cord blood and peripheral blood. The Company's Quality Assurance Program will be a key factor in moving forward to finalize contracts with several entities for the processing and storage of stem cells from cord blood and peripheral blood.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (www.BMSN.us) is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation. Bio-Matrix' new 15,000 sq. ft. state-of-the-art facility, located in the heart of San Diego's biotechnology corridor, houses Bio-Matrix' two secure Cryogenic Stem Cell Banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories.

DISCLAIMER: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Source: Business Wire

More News in this Category